Health Care·Biotechnology·$28.9B
Natera Inc is a biotechnology company focused on genetic testing and diagnostics, particularly in the areas of reproductive health and oncology. With a market cap of $29 billion, it plays a significant role in advancing personalized medicine and improving patient outcomes through its innovative testing solutions.
EPS (Earnings Per Share)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
Revenue growth is essential for assessing the company's ability to expand its market share and maintain competitive advantage.
1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
63%
Avg EPS Surprise
-20.79%
Avg Stock Reaction
+1.32%
In the last quarter, Natera reported a larger-than-expected loss, which surprised analysts. Despite this, the stock saw a slight uptick the following day, indicating some investor optimism.
Management Promises & Guidance
Overall, expectations are mixed as the company has struggled with profitability but has shown potential for growth in its testing services. Investors are looking for signs of improvement in both EPS and revenue.
Bull Case
If Natera can demonstrate significant growth in test volumes and manage costs effectively, it may lead to a positive surprise in earnings and revenue.
Bear Case
On the other hand, continued losses and lack of revenue growth could lead to further declines in stock price, especially if the company fails to meet investor expectations.
EPS (Earnings Per Share)
N/AEPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/ARevenue growth is essential for assessing the company's ability to expand its market share and maintain competitive advantage.
Test Volume
N/AThe volume of tests conducted is a direct measure of demand for Natera's services and can indicate future revenue potential.
The print will turn on these two things.
Q1
What specific growth figures can Natera provide regarding test volumes this quarter?
Investors will be closely watching for any signs of increased demand, as this could significantly impact future revenue.
Q2
How does Natera plan to address its ongoing losses and improve profitability?
Management's strategy for improving financial performance will be crucial for investor confidence and stock performance.
Why consensus could be wrong
The Street may be underestimating Natera's potential for recovery in test volume growth, especially in oncology, which could lead to a stronger-than-expected performance this quarter.
Supporting Evidence
Natera's recent investments in marketing and customer engagement may yield higher test volumes.
Historical trends show that the company has often exceeded expectations in periods of increased demand.
The lack of options data suggests uncertainty, which may lead to a surprise if results are better than anticipated.
Key Risk
If test volumes exceed expectations significantly, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around Natera's ability to convert test volume growth into profitability amidst ongoing financial challenges.
Bull Confirmed If
A significant increase in test volume growth of over 20% compared to the previous quarter would confirm the bull case.
Bear Confirmed If
Continued losses exceeding $1.50 per share would confirm the bear case.
Implied Move
±N/A
There is currently no options market data available to gauge investor sentiment ahead of the earnings report.
Cross-company pattern from 30 similar setups.
Prior-quarter miss setup in Health Care
n=30Fade rate: 10 of 27 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 17 of 27 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.7%, with a raw directional average of +3.7% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Natera beats expectations, history suggests a potential average one-day stock move of +1.43%, confirming positive sentiment around growth.
In-Line / Cautious
An in-line report could lead to a muted response, reflecting cautious optimism as investors await more concrete guidance.
Miss
If Natera misses expectations, history suggests a potential average one-day move of +1.14%, which could further dampen investor sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026